We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

An array of pharmaceutical pills with the company's logo on the bottle ... So why not let those who can't diet or exercise ...

“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... Although Asness doesn't harbor good prospects for Bitcoin, he stated that he wouldn't short the cryptocurrency ...

In this article, we are going to take a look at where Eli Lilly and Company ... they aren’t as strong as Wall Street was hoping.” Cramer noted that the company had a volatile recently ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks on Jim Cramer's radar. Jim Cramer, host of Mad Money, recently emphasized the ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Eli Lilly is experiencing ... While this is all great news for Verzenio, Lilly isn't stopping its ambitions in oncology care with just one treatment. Right now, the company has seven clinical ...

Truist Financial lifted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th.